Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-74.5%-9.9pp-64.7%
Return on assets-60.4%-6.5pp-53.9%+7.3pp-61.2%
Return on invested capital-94.5%+21.9pp-116.4%
Liquidity
Current ratio8.1×+0.4×7.8×+2.6×5.2×-0.2×5.4×-2.1×7.4×-1.2×
Quick ratio8.1×+0.4×7.8×+2.6×5.2×-0.2×5.4×-2.1×7.4×-1.2×
Cash ratio1.1×-2.3×3.4×+2.4×-0.3×1.3×-0.4×1.7×-1.2×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Interest coverage-144.7×+202×-346.6×+2,004×-2,350.5×-599×-1,751.3×-445×-1,306.1×-302×
Per Share
Book value per share$3.24-38.3%$5.25+50.0%$3.50-18.0%$4.27-17.7%$5.18-25.5%
Valuation
Market capitalization$498.52M+276%$560.3M+116%$259.47M+88.2%$137.87M+65.5%$83.32M-48.4%
Enterprise value$475.49M+475%$440.81M+91.4%$230.33M+155%$90.35M+171%$33.39M-54.8%
Price / book2.5×+2.0×2.4×+0.7×1.7×+1.0×0.7×+0.4×0.4×-0.2×
Earnings yield-31.4%+78.2pp-28.8%+33.3pp-62%+53.1pp-115.1%+59.4pp-174.5%-95.6pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Kyverna Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Kyverna Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.